Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of NY-ESO-1c259T in HLA-A2-positive synovial sarcoma
2015-005594-21Phase 2Terminated
- Sponsor
- Adaptimmune Therapeutics
- Start
- Jun 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel in synovial sarcoma (SS), sponsored by Adaptimmune Therapeutics. Started Jun 2016; status: terminated.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on 2015-005594-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005594-21.